Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial-Reference-Cited by-同舟云学术

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

Published:2012-04 Issue:4 Volume:13 Page:345-352
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Masuda Norikazu,Sagara Yasuaki,Kinoshita Takayuki,Iwata Hiroji,Nakamura Seigo,Yanagita Yasuhiro,Nishimura Reiki,Iwase Hirotaka,Kamigaki Shunji,Takei Hiroyuki,Noguchi Shinzaburo

Publisher

Elsevier BV

Subject

Oncology

Reference32 articles.

1. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association study;Jonat;J Clin Oncol,2002

2. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy;Sverrisdottir;J Clin Oncol,2004

3. Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5

4. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer;Jonat;Eur J Cancer,1995

5. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer;Sverrisdottir;Breast Cancer Res Treat,2011

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Therapy: Current Landscape and Future Horizons for ER-Positive/HER2-Negative and Triple-Negative Early Breast Cancer;Current Treatment Options in Oncology;2024-08-15

2. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

3. Morphological and molecular changes of oestrogen receptor‐positive breast cancer following bridging endocrine therapy: a United Kingdom multicentre study;Histopathology;2024-06-07

4. Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysis;Expert Review of Anticancer Therapy;2024-05-17

5. Machine learning enables identification of an alternative yeast galactose utilization pathway;Proceedings of the National Academy of Sciences;2024-04-26